{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:53:54Z","timestamp":1782910434153,"version":"3.54.5"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The prognosis of melanoma has significantly improved since the introduction of immune checkpoint inhibitor (ICI) therapies. While ICIs are associated with a range of immune-related adverse events (irAEs), these reactions may occur early or late during treatment. Neutrophilic dermatoses, including pyoderma gangrenosum, are commonly observed in patients with systemic inflammatory disease, but have also been reported as rare cutaneous irAEs. To further characterize this rare phenomenon, we present the case of a 45-year-old patient with stage IIB cutaneous melanoma who underwent surgical resection of the primary tumor with split-thickness skin graft coverage, followed by adjuvant therapy with the PD-1 inhibitor nivolumab. During the one-year course of immunotherapy, the donor site of the graft exhibited persistent non-healing and progressive ulceration. However, it did not extend beyond the boundaries of the initial harvest site. Of note, the recipient site at the left heel healed without complications. The lesion was biopsied after completion of immunotherapy. Histopathological analysis revealed a neutrophilic dermatosis with PG-like features. The lesion showed rapid improvement upon initiation of dapsone therapy, which is in line with its action on neutrophils. This case underscores the diagnostic challenge posed by atypical cutaneous irAEs, particularly when localized and lacking systemic features. Awareness of such rare presentations is crucial to enable timely recognition and appropriate treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1730549","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:33:21Z","timestamp":1782909201000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Localized neutrophilic dermatosis at a split-skin donor site during PD-1 blockade: a unique immune-related adverse event"],"prefix":"10.3389","volume":"17","author":[{"given":"Veselina","family":"Moravenova","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University","place":["Mainz, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Wilhelm","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University","place":["Mainz, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Veeser","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University","place":["Mainz, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klajdi","family":"Begaj","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University","place":["Mainz, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Weidenthaler-Barth","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University","place":["Mainz, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Grabbe","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University","place":["Mainz, Germany"]},{"name":"Research Center for Immunotherapy (FZI), Medical Center of the Johannes Gutenberg University Mainz","place":["Mainz, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henner","family":"Stege","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University","place":["Mainz, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Wittmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University","place":["Mainz, Germany"]},{"name":"Research Center for Immunotherapy (FZI), Medical Center of the Johannes Gutenberg University Mainz","place":["Mainz, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.e21503","article-title":"Five-year survival outcomes in patients with melanoma with complete response to immunotherapy who discontinue therapy","volume":"41","author":"Bleiberg","year":"2023","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447021","article-title":"Toxicity in the era of immune checkpoint inhibitor therapy","volume":"15","author":"Keam","year":"2024","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1101a155","article-title":"Cutaneous adverse events of immune checkpoint inhibitors: A literature review","volume":"11","author":"Apalla","year":"2021","journal-title":"Dermatol Pract Concept"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8621-8","article-title":"A comprehensive review of neutrophilic diseases","volume":"54","author":"Marzano","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5070\/d3274053158","article-title":"Pembrolizumab-associated pyoderma gangrenosum in a patient with metastatic squamous cell carcinoma","volume":"27","author":"Tsibris","year":"2021","journal-title":"Dermatol Online J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/jcia.2024.13751","article-title":"Postoperative pyoderma gangrenosum in a patient undergoing long-term nivolumab therapy","volume":"7","author":"Sato","year":"2024","journal-title":"J Cutaneous Immunol Allergy"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13074","article-title":"Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review","volume":"32","author":"Ravi","year":"2019","journal-title":"Dermatol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01931-3","article-title":"Pyoderma gangrenosum: Treatment options","volume":"83","author":"Dissemond","year":"2023","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.19-3-224","article-title":"Pyoderma gangrenosum - a guide to diagnosis and management\u2002Clin Med (Lond)","volume":"19","author":"George","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4103\/jipo.jipo_11_18","article-title":"Pyoderma gangrenosum following initiation of immune checkpoint inhibitor therapy","volume":"1","author":"Welborn","year":"2020","journal-title":"J Immunotherapy Precis Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1425454","article-title":"Hematological Malignancy-associated pyoderma gangrenosum: Evaluating the magnitude of the association","volume":"11","author":"Kridin","year":"2024","journal-title":"Front Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.04.026","article-title":"Chronic atrophic erosive dermatosis of the scalp and extremities: A recharacterization of erosive pustular dermatosis","volume":"57","author":"Patton","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16401","article-title":"The PARACELSUS score: A novel diagnostic tool for pyoderma gangrenosum","volume":"180","author":"Jockenh\u00f6fer","year":"2019","journal-title":"Br J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25545","article-title":"Pyoderma gangrenosum masquerading as wound infection in the early postoperative period after lumbar spine deformity correction surgery","volume":"14","author":"Owen","year":"2022","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/103.5.359","article-title":"Neutrophilic disease of the skin and intestines after ipilimumab treatment for Malignant melanoma - simultaneous occurrence of pyoderma gangrenosum and colitis","volume":"24","author":"Rudolph","year":"2014","journal-title":"Eur J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"adv9646","DOI":"10.2340\/actadv.v103.9646","article-title":"Atezolizumab plus bevacizumab-induced recalcitrant pyoderma gangrenosum treated with baricitinib: A case report","volume":"103","author":"Kim","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.962669","article-title":"PD-L1(+) neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab","volume":"13","author":"Cristinziano","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010541","article-title":"Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer","volume":"13","author":"Roudko","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2020-206540","article-title":"Nivolumab-associated active neutrophilic gastritis","volume":"73","author":"Rovedatti","year":"2020","journal-title":"J Clin Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.5070\/d330464106","article-title":"Nivolumab-induced hidradenitis suppurativa: A case report","volume":"30","author":"Lamberg","year":"2024","journal-title":"Dermatol Online J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228790","article-title":"The immune functions of keratinocytes in skin wound healing","volume":"21","author":"Piipponen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.1171700","article-title":"Topographical and temporal diversity of the human skin microbiome","volume":"324","author":"Grice","year":"2009","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2537","article-title":"The skin microbiome","volume":"9","author":"Grice","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/molecules30010113","article-title":"Dapsone alters phenotypical and functional properties of human neutrophils in vitro","volume":"30","author":"Rako\u010devi\u0107","year":"2025","journal-title":"Molecules"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1730549\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:33:22Z","timestamp":1782909202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1730549\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2026.1730549"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1730549","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1730549"}}